US 12,077,760 B2
DNA aptamers and use thereof for the treatment of cancer
Gabriel Lopez-Berestein, Houston, TX (US); Paola Amero, Houston, TX (US); Cristian Rodriguez-Aguayo, Houston, TX (US); Rahul Mitra, Houston, TX (US); Anil K. Sood, Houston, TX (US); Vittorio De Franciscis, Naples (IT); David Volk, Houston, TX (US); and Lokesh Ganesh L. Rao, Houston, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US); and Consiglio Nazionale delle Ricerche, Rome (IT)
Appl. No. 17/413,550
Filed by Board of Regents, The University of Texas System, Austin, TX (US); and Consiglio Nazionale delle Ricerche, Rome (IT)
PCT Filed Dec. 16, 2019, PCT No. PCT/US2019/066654
§ 371(c)(1), (2) Date Jun. 12, 2021,
PCT Pub. No. WO2020/124095, PCT Pub. Date Jun. 18, 2020.
Claims priority of provisional application 62/780,058, filed on Dec. 14, 2018.
Prior Publication US 2022/0380766 A1, Dec. 1, 2022
Int. Cl. C12N 15/115 (2010.01); A61K 31/337 (2006.01); A61K 33/243 (2019.01); A61P 35/00 (2006.01)
CPC C12N 15/115 (2013.01) [A61K 31/337 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); C12N 2310/16 (2013.01); C12N 2310/313 (2013.01); C12N 2310/322 (2013.01); C12N 2310/351 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01); C12N 2320/32 (2013.01)] 14 Claims
 
1. An AXL receptor-kinase binding DNA aptamer comprising a dithiophosphate backbone linkage, wherein the sequence of the DNA aptamer is at least 95% identical to the sequence of SEQ ID NO: 1, and wherein the dithiophosphate backbone is (i) at position 25 of SEQ ID NO: 1 or (ii) at position 4 of SEQ ID NO: 1.